A Pilot Study Evaluating Surrogates of Response to Short Term Oral Suberoylanilide Hydroxamic Acid (SAHA) in Women With New Diagnosed Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 25 May 2018
At a glance
- Drugs Vorinostat (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 May 2018 Last checked against ClinicalTrials.gov record.
- 07 Jun 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.